Improved Glucose Control and Reduced Body Weight in Rodents with Dual Mechanism of Action Peptide Hybrids

Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2013) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents

(2012) Jonathan W. Day et al.   BIOPOLYMERS

Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents

(2012) J. D. Roth et al.   DIABETES OBESITY & METABOLISM

A review of late-stage CNS drug candidates for the treatment of obesity

(2012) D J Heal et al.   INTERNATIONAL JOURNAL OF OBESITY

GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities

(2011) Jonathan D Roth et al.   BRITISH JOURNAL OF PHARMACOLOGY

Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates

(2010) Nicholas T. Bello et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Multi-hormonal weight loss combinations in diet-induced obese rats: Therapeutic potential of cholecystokinin?

(2010) James L. Trevaskis et al.   PHYSIOLOGY & BEHAVIOR

Harmonizing the Metabolic Syndrome

(2009) K.G.M.M. Alberti et al.   CIRCULATION

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

(2009) A. Pocai et al.   DIABETES

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight

(2009) C M Mack et al.   INTERNATIONAL JOURNAL OF OBESITY

Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury

(2009) Leo Timmers et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology

Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy

(2009) Eric Ravussin et al.   Obesity

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity

(2008) S. R. Smith et al.   DIABETES CARE

Amylin-Mediated Restoration of Leptin Responsiveness in Diet-Induced Obesity: Magnitude and Mechanisms

(2008) James L. Trevaskis et al.   ENDOCRINOLOGY

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET

Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies

(2008) J. D. Roth et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart

(2007) David P. Sonne et al.   REGULATORY PEPTIDES